5-FU


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

5-FU

(pharmacology)
Mentioned in ?
References in periodicals archive ?
Current dosing of 5-FU based on Body Surface Area (BSA) results in up to a 30-fold variability in patient blood levels.
The most common grade 3 or 4 adverse events that occurred more frequently in the ONIVYDE in combination with 5-FU and leucovorin arm (>2% incidence versus 5-FU and leucovorin) were neutropenia, diarrhea, vomiting, and fatigue.
The effects of 5-FU and SBE on growth of Bel-7402, HCT-8 and L02 cells were evaluated by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)/phenazine methosulfate (PMS) assay.
In 1999, Brienza et al (15) published a European multi-center compassionate use program experience of oxaliplatin with bolus/infusion 5-FU in 206 5-FU pretreated patients with advanced CRC.
Uridine triacetate is an investigational drug currently under development for use as a treatment for overexposure to 5-FU due to dosing errors or impaired clearance of 5-FU from the body.
4] cells/well) and incubated with various concentrations of anticancer drugs (0-150 [micro]M DMC, 0-1 mg/ml 5-FU and 0-8 [micro]g/ml DOX.
Louise Makin, BTG's Chief Executive Officer, commented: "There is currently no available antidote for 5-FU overexposure, so uridine triacetate will meet a real need if approved.
In the present study the synergistic effect and mechanisms of action of combinations of [beta]-aescin and 5-FU were investigated in human hepatocellular carcinoma SMMC-7721 cells, and the Isobole-method/interaction-index analysis was used to assess the effect of drug combinations.
The National Institutes of Health estimate that 275,000 patients in the United States undergo 5-FU therapy annually, and 1,300 die from 5-FU overexposure resulting from accidental overdoses or poor drug clearance.
All patients will receive a biweekly infusional regimen consisting of an initial dose of 400mg/m2 of 5-FU followed by 600 mg/m2 of 5-FU via a 22-hour infusion on days 1 and 2.
In addition, the results from our Phase II colorectal cancer trial for end-stage patients led us to initiate a Phase II trial to evaluate DAVANAT([R]) with AVASTIN([R]), 5-FU and leucovorin as a first line treatment for locally advanced, unresectable or metastatic colorectal cancer in patients unable to tolerate intensive chemotherapy.
Time to tumor progression and safety results from the Phase II CoFactor plus 5-FU trial: